Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.
Factors such as the rising prevalence of dermatophytic onychomycosis, heavy investments to develop therapies, and frequent product innovations will aid in the steady growth of this market during the forecast period. An important factor that will impel the prospects for growth in this market is the augmented focus on combination therapies. Recently, it has been observed that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. Since combination therapies have improved clinical efficiency and are more cost-effective than terbinafine, they are increasingly being preferred over individual terbinafine-based therapies as they have a higher cure rate.
The global dermatophytic onychomycosis market is intensely competitive owing to the presence of numerous small and large vendors that operate at a local or global scale. To survive and succeed in this market, the vendors enter into strategic alliances with smaller players to manufacture and market new drugs.
The Americas dominated this market and is envisaged to retain its dominating market position by the end of 2020 owing to the presence of a well-developed healthcare system

The global Dermatophytic Onychomycosis market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Dermatophytic Onychomycosis volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dermatophytic Onychomycosis market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Dermatophytic Onychomycosis in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Dermatophytic Onychomycosis manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Anacor Pharmaceuticals
Galderma
Janssen Biotech
Novartis
Valeant Pharmaceuticals
Abeona Therapeutics
Allergan
Elorac
GlaxoSmithKline
Hexima
Hisamitsu Pharmaceutical
Mayne Pharma
MediQuest Therapeutics
Meiji Seika Pharma
Merz Pharma
Moberg Pharma
NanoBio
NovaBiotics
Nuvo Research
Pfizer
Polichem
Promius Pharma
Sanofi
Seren Pharmaceuticals
Taro Pharmaceutical
Topica Pharmaceuticals
Viamet Pharmaceuticals

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Oral
Topical

Segment by Application
Hospitals
Clinics and laboratories
Others